Vorotx
San Diego, US · 1 known investors
Voro Therapeutics develops tumor-activated biologics, specifically an antibody-based platform called PrimeBody™, designed to treat cancers including colorectal, gastric, prostate, and lung cancers while minimizing systemic toxicity. The company leverages masking technology and conditionally activated linkers to enable systemic delivery with tumor-specific activation.
BiotechMedical Devices